High-Throughput Analysis of Volatile Compounds in Air, Water, and Soil Using SIFT-MS ...

Accelerated approval was based on promising results from the ongoing Phase III BREAKWATER trial. The FDA has granted accelerated approval to Pfizer’s Braftovi (encorafenib) in combination with ...

In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, explores the key factors driving the increasing number of partnerships between telehealth and ...

In the third part of this roundtable discussion, experts discuss the issues with data that AI must overcome. Pharmaceutical Executive recently brought together a group of experts to discuss the ...

Talking about ethics isn’t exactly exciting. Leaders don’t usually jump at the chance to emphasize following rules or exceeding standards—it’s much more appealing to focus on growth than on problems.

John Aiken, Senor Director, Training & Talent Development, Veloxis Pharmaceuticals;Jennifer Troiano, Territory Manager, Sandoz Pharmaceuticals;Kumar Erramilli, Chief ...

New technology is making it easier for more companies to embrace telehealth, which in turn is providing more opportunities for pharma companies to interact with HCPs and patients. Peter Ax, founder ...

Approval was based on positive results from the Phase III balance study, where Tryngolza demonstrated a notable placebo-adjusted triglyceride reduction at 12 months. The FDA has approved Ionis ...

GLP-1s are the most discussed drug of 2024. While they were initially developed to treat diabetes, the drug’s ability to help with weight loss has made them extremely popular. So much so that in 2023, ...

These professionals in the healthcare marketing sector have been chosen by their peers for making big moves and taking on larger roles. The pharmaceutical industry is undergoing a transformative era, ...

Click the title above for a link to open the Pharmaceutical Executive December 2024 issue in an interactive PDF format.

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA ...